Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
Price : $35 *
At a glance
- Drugs Dendritic cell activated cytokine-induced killer cells-Shenzhen Hornetcorn (Primary) ; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Shenzhen Hornetcorn Biotechnology
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2015 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 05 Jun 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.